Precision oncology is transforming the field of cancer research and clinical care by emphasizing individualized treatment strategies that leverage the molecular and cellular profiles of each patient. As our knowledge of tumor biology expands, we are witnessing the convergence of groundbreaking technologies such as patient-derived organoids, multi-omics profiling, and liquid biopsy. These technologies offer unparalleled insights into the complexities of tumor heterogeneity, therapy resistance, and disease progression. Despite significant advancements, challenges remain in translating these discoveries into clinical practice, highlighting the necessity for continued research and integration.

This Research Topic aims to consolidate state-of-the-art insights from molecular biology, high-throughput omics technologies, advanced organoid models, and clinical oncology. Our primary objectives include enhancing the predictive power of preclinical models, facilitating patient-specific diagnostics and therapies, identifying novel therapeutic targets, and bridging the existing gap between laboratory discoveries and clinical applications. By focusing on the translational relevance of precision oncology, we endeavor to support the development of strategies that enhance patient outcomes and optimize personalized cancer treatment.

To gather further insights into the multifaceted domain of precision oncology, we welcome articles addressing, but not limited to, the following themes:

- Molecular mechanisms driving tumor progression, heterogeneity, metastasis, and drug resistance.
- High-throughput omics approaches (genomics, transcriptomics, proteomics, metabolomics) for biomarker discovery.
- Applications of 3D organoid and spheroid models in cancer research and therapeutic screening.
- Development and application of patient-derived organoid models in cancer research and drug screening.
- Integration of artificial intelligence, machine learning, and big data in precision oncology.
- Personalized approaches to genitourinary, gastrointestinal, and HPV-related cancers.
- Translational studies and clinical trials applying precision medicine.
- Ethical and regulatory challenges in implementing personalized cancer care.
- Liquid biopsy approaches including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes.

Please note the following conflict of interest disclosures for Dr. Betul Karademir Yilmaz:
- Dr. Yilmaz is the co-founder of Cellformatics Biotechnology Ltd Co.
Dr. G. Hossein Ashrafi and Dr. Mustafa Ozdogan declared no conflict of interest.

Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases, which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this Research Topic.

Are you interested in contributing a manuscript to this Research Topic?

Precision Oncology: Integrating Molecular Mechanisms, Organoid Models, and Omics Technologies for Personalized Cancer Care

Topic Coordinator